Immunovia - Termination of coverage
Edison Investment Research is terminating coverage on NetCents, AEX Gold, Immunovia and JPMorgan Global Convertibles Income Fund. Please note you...
1.1k Views
Immunovia - Exploring new avenues
Immunovia has announced that it needs to optimise the algorithms used in the IMMray PanCan-d test in high-risk patients due to sample...
45 Views
Immunovia - IMMray PanCan-d approaches the market
Immunovia is preparing to market its IMMray PanCan-d for self-pay patients at high risk of pancreatic cancer (PC) in Q418, after preparatory...
79 Views
Immunovia - Preparing to tackle big markets
Immunovia continues to leverage the IMMray technology to additional opportunities with prospective trials in the group of early pancreatic cancer...
85 Views
New opportunities in sight as first sales approach
Immunovia is on track to start commercialising its PanCan-d test for the early detection of pancreatic cancer in high-risk patients in 2018. To...
93 Views
No more insights